Analysis Research

 
Stock Quotes for Analysis Research top ^
  • Industry: Software - Application
  • Sector: Technology
  • Stock Type: Classic Growth
Sign-up for iaic investment picks
  • Industry: Software - Application
  • Sector: Technology
  • Stock Style: Large Core
  • Stock Type: Slow Growth
Sign-up for iaic investment picks

 
Fund Quotes for Analysis Research top ^
  • Category: Nontraditional Bond
  • Morningstar Rating: 2 Stars
Sign-up for flsmx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 3 Stars
Sign-up for flsfx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 3 Stars
Sign-up for flsix investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 3 Stars
Sign-up for flsrx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 1 Stars
Sign-up for flslx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 2 Stars
Sign-up for flslx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 2 Stars
Sign-up for FLSLX investment picks

 
News Articles for Analysis Research top ^
Waters Corporation (WAT:NYSE) today announced it received the 2014 Product Innovation Award for PATROL UPLC ® Process Analysis System from Frost & Sullivan in the Global Process Liquid Chromatography market.
Sign-up for Waters PATROL UPLC Process Analysis System Receives Product Innovation Leadership Award from Frost & Sullivan investment picks
2014/9/24
Total pay for outside directors at the nation’s largest corporations increased by 6% in 2013, fueled by higher stock-based compensation, according to a new analysis by global professional services company Towers Watson (NYSE, NASDAQ: TW). The study also found that cash compensation remained flat for the first time since 2007, when proxy disclosure rules were enacted requiring companies to report actual values received by directors in summary compensation tables.
Sign-up for Compensation for U.S. Corporate Directors Increased 6%, Towers Watson 2014 Analysis Finds investment picks
-Profile Supports Potential Role in Modulating Tumor Microenvironment in Blood-Related Cancers, Including AML, MDS, CMML and CLL- -Analysis Also Provides Scientific Basis for Pacritinib's Lack of Myelosuppression, a Unique Attribute Among Agents in Development for Myelofibrosis- SEATTLE , Dec.
Sign-up for CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers investment picks
2014/12/11
CA Technologies (NASDAQ:CA) today announced it has been positioned by Gartner, Inc. in the Leaders quadrant of the “ Magic Quadrant for Integrated IT Portfolio Analysis Applications ”* for the third year in a row.
Sign-up for CA Technologies Positioned as “Leader” in Gartner Magic Quadrant Report for Integrated IT Portfolio Analysis Applications for Third Consecutive Year investment picks
Ophthotech Corporation (Nasdaq:OPHT) today announced that a subgroup analysis assessing the development and progression of sub-retinal fibrosis in the Company's Phase 2b trial comparing Fovista ® (1.5mg) combination therapy with Lucentis ® (0.5mg) versus Lucentis ® (0.5mg) monotherapy will be presented at the American Academy of Ophthalmology 2014 Annual Meeting in Chicago, Illinois.
Sign-up for Ophthotech Announces Fovista® Phase 2b Independent Analysis Shows that Fovista® Anti-PDGF Therapy, Combined with Anti-VEGF Therapy, is Associated with a Reduction of Sub-retinal Fibrosis in Wet AMD Patients investment picks
WOODCLIFF LAKE, N.J. and SAN DIEGO , Oct.
Sign-up for Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ® (lorcaserin HCl) CIV in Postgraduate Medicine investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Analysis Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Amtrust Financial Services  |  Next: Analysis Services